DE69121561T2 - Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht - Google Patents

Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht

Info

Publication number
DE69121561T2
DE69121561T2 DE69121561T DE69121561T DE69121561T2 DE 69121561 T2 DE69121561 T2 DE 69121561T2 DE 69121561 T DE69121561 T DE 69121561T DE 69121561 T DE69121561 T DE 69121561T DE 69121561 T2 DE69121561 T2 DE 69121561T2
Authority
DE
Germany
Prior art keywords
treating
addiction
medicine
producing
guanidinopropionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69121561T
Other languages
English (en)
Other versions
DE69121561D1 (de
Inventor
Martin Meglasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of DE69121561D1 publication Critical patent/DE69121561D1/de
Application granted granted Critical
Publication of DE69121561T2 publication Critical patent/DE69121561T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
DE69121561T 1990-02-28 1991-02-27 Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht Expired - Fee Related DE69121561T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48661590A 1990-02-28 1990-02-28
PCT/US1991/000334 WO1991012799A1 (en) 1990-02-28 1991-01-22 Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
PCT/US1991/001109 WO1991012800A1 (en) 1990-02-28 1991-02-27 Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

Publications (2)

Publication Number Publication Date
DE69121561D1 DE69121561D1 (de) 1996-09-26
DE69121561T2 true DE69121561T2 (de) 1997-01-30

Family

ID=26782896

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69121561T Expired - Fee Related DE69121561T2 (de) 1990-02-28 1991-02-27 Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht

Country Status (14)

Country Link
US (2) US5132324A (de)
EP (2) EP0713699A2 (de)
JP (2) JPH0825875B2 (de)
KR (1) KR100190257B1 (de)
AT (1) ATE141505T1 (de)
AU (2) AU7316591A (de)
CA (1) CA2073873C (de)
DE (1) DE69121561T2 (de)
DK (1) DK0517820T3 (de)
ES (1) ES2090317T3 (de)
GR (1) GR3021424T3 (de)
NZ (2) NZ237249A (de)
WO (2) WO1991012799A1 (de)
ZA (1) ZA911496B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US6008253A (en) * 1991-08-26 1999-12-28 The Upjohn Company Use of 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity in a mammal
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
WO1994026261A1 (en) * 1993-05-14 1994-11-24 Amira, Inc. Treating body parts susceptible to ischemia using creatine analogs
US5808246A (en) * 1995-09-25 1998-09-15 Otis Elevator Company Triac drive for three-phase line-powered linear induction motor elevator door operator
AU721190B2 (en) * 1995-10-11 2000-06-29 Avicena Group, Inc. Use of creatine analogues for the treatment of disorders of glucose metabolism
AU1307697A (en) * 1995-12-22 1997-07-17 Smithkline Beecham Plc Aminoguanidine for treating niddm
US20040122096A1 (en) * 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
CA2280871A1 (en) * 1997-02-13 1998-08-20 Valerie Piercy Use of nitric oxide synthase inhibitors for the treatment of diabetes
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1108434B1 (de) 1998-08-24 2014-05-14 Kurokawa, Kiyoshi Medikamente zur verringerung der carbonylbelastung und peritonealdialysate
US7014307B2 (en) * 1998-11-09 2006-03-21 Silverbrook Research Pty Ltd Printing unit for an image recordal and generation apparatus
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP4777225B2 (ja) * 2006-12-04 2011-09-21 キヤノン株式会社 吐出用液体及び吐出方法
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2012138214A1 (en) * 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN105963250A (zh) * 2016-06-21 2016-09-28 俞力 一种口服葡萄糖溶液及其制备方法
KR102615692B1 (ko) * 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA891509A (en) * 1972-01-25 Beecham Group Limited Esters and amides of guanidine aliphatic acids
GB1153424A (en) * 1965-04-15 1969-05-29 Horlicks Ltd Pharmaceutical Compositions
GB1195199A (en) * 1966-11-25 1970-06-17 Horlicks Pharmaceuticals Ltd Improvements in Compositions comprising Insulin.
GB1195200A (en) * 1967-02-07 1970-06-17 Horlicks Pharmaceuticals Ltd Pharmaceutical Compositions.
US3843798A (en) * 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
GB1552179A (en) * 1976-11-02 1979-09-12 Beecham Group Ltd Pharmaceutical compositions for treating hyperglycaemia
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid

Also Published As

Publication number Publication date
EP0517820A1 (de) 1992-12-16
ZA911496B (en) 1991-12-24
CA2073873A1 (en) 1991-08-29
DE69121561D1 (de) 1996-09-26
NZ237249A (en) 1994-09-27
ATE141505T1 (de) 1996-09-15
JPH0820534A (ja) 1996-01-23
WO1991012800A1 (en) 1991-09-05
US5132324A (en) 1992-07-21
AU7316591A (en) 1991-09-18
JPH05505189A (ja) 1993-08-05
KR100190257B1 (ko) 1999-06-01
JP2637712B2 (ja) 1997-08-06
ES2090317T3 (es) 1996-10-16
US5134164A (en) 1992-07-28
EP0713699A3 (de) 1996-07-10
EP0517820B1 (de) 1996-08-21
AU645076B2 (en) 1994-01-06
GR3021424T3 (en) 1997-01-31
EP0713699A2 (de) 1996-05-29
NZ245541A (en) 1997-05-26
DK0517820T3 (da) 1997-06-09
AU7485091A (en) 1991-09-18
JPH0825875B2 (ja) 1996-03-13
CA2073873C (en) 1996-10-29
WO1991012799A1 (en) 1991-09-05

Similar Documents

Publication Publication Date Title
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE446101T1 (de) Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69113386T2 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
ATE143590T1 (de) Verfahren zur herstellung von stabilen, hydrophilen oder ambiphilen creme-zubereitungen, enthaltend vesikuläre bestandteile, und deren verwendung
NO179245C (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
DE69116606D1 (de) Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee